LivaNova Reports 10.8% Revenue Growth to $390.6 Million in Q2 2026

LivaNova PLC reported a significant increase in its financial performance for the second quarter of 2026, with net revenue reaching $390.6 million, up 10.8% from $352.5 million in the same period last year. For the first half of 2026, the company generated $752.8 million in revenue, a 12.5% increase compared to $669.4 million in the first half of 2025. The gross profit for the quarter was $273.7 million, resulting in a gross margin of 70.0%, compared to 67.8% in the prior year. The company reported a net income of $108.6 million for the quarter, a substantial increase from $27.2 million in Q2 2025, and a net income of $130.9 million for the first half of 2026, compared to a loss of $300.2 million in the same period last year.

The company’s operating income for the second quarter was $49.5 million, down from $54.2 million in Q2 2025, primarily due to increased litigation provisions related to its 3T Heater-Cooler device. Operating expenses rose to $224.2 million for the quarter, driven by higher selling, general, and administrative (SG&A) expenses, which increased to $158.1 million from $137.8 million in the previous year. Research and development (R&D) expenses also increased to $53.7 million, reflecting ongoing investments in product development.

LivaNova's strategic developments included the FDA's premarket approval of the aura6000 System for obstructive sleep apnea, which is expected to enhance the company's Neuromodulation segment. The company reported strong growth across its segments, with Cardiopulmonary revenue increasing by 11.2% to $221.6 million and Neuromodulation revenue rising by 10.1% to $166.9 million in Q2 2026. The company also noted a favorable product mix and strong demand for consumables as key drivers of growth.

Geographically, LivaNova experienced revenue growth in all regions, with the U.S. market contributing $199.4 million, up 5.8%, while Europe and the Rest of the World saw increases of 22.5% and 12.5%, respectively. The company’s total assets as of June 30, 2026, were $2.64 billion, with cash and cash equivalents amounting to $516.6 million. LivaNova's current liabilities decreased to $707.0 million from $808.1 million at the end of 2025, reflecting improved liquidity management.

Looking ahead, LivaNova remains optimistic about its growth trajectory, driven by new product launches and expanding market presence. The company anticipates continued revenue growth, although it acknowledges potential challenges from macroeconomic factors, including foreign exchange volatility and supply chain constraints. LivaNova's management believes that its current liquidity position, combined with operational cash flow, will be sufficient to meet its financial obligations and support ongoing investments in innovation and growth.